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in pre-pubertal children with idiopathic GH Deficiency (GHD) and Turner Syn-
drome (TS). The long-term prediction of height was validated in new cohorts of
pre-pubertal children with GHD (n 664) or TS (n607) from KIGS. RESULTS:When
height was simulated from GH start in GHD, the predicted mean (SD) gain after 4
years was 30.4 (3.4) cm; the observed height gain was 30.0 (5.0) cm. In TS the
corresponding predicted and observed mean gains were 27.2 (2.2) and 26.5 (3.8) cm.
CONCLUSIONS: Sequential application of annual KIGS growth prediction models
permits accurate simulation of height development during the first four years of
GH treatment in GHD and TS and is applicable for patient groups from GH start.
Long-term growth simulation helps managing patient’s expectations and facili-
tates an individualised, cost effective growth hormone (GH) therapy in children.
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STUDYING HETEROGENEITY IN TREATMENT RESPONSE IN WOMEN WITH
IDIOPATHIC MENORRHAGIA TREATED WITH LEVONORGESTREL-RELEASING
INTRAUTERINE SYSTEM (LNG-IUS): APPLICATION OF INNOVATIVE METHODS
TO IDENTIFY DIFFERENTIAL RESPONSE
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OBJECTIVES: To establish whether there are subsets of women with idiopathic
menorrhagia who experience differential health-related quality of life (HRQL) ben-
efits with LNG-IUS treatment, and which factors could be attributed to those
differences. METHODS: Data for women with idiopathic menorrhagia residing in
India, Russia and Turkey were derived from a prospective, 12-month observational
study. Latent profile analysis (LPA) was used to identify unknown subgroups of
differential responders on the Mental Component Summary (MCS) of the SF-36v2.
Post hoc analyses were performed to characterize identified subgroups using base-
line and 12 month data. RESULTS: Overall improvement in MCS scores from base-
line to 12 months was 8.4 points. LPA analyses revealed two distinct subsets of
patients: one smaller subset (30% of the sample) showed a smaller improvement
(2.3 points) than the improvement overall and are thus referred to as ‘partial-
responders.’ A larger subgroup (70% of the sample) was identified with a much
greater improvement (11.3 points) than that overall, thus referred to as ‘respond-
ers’. Post hoc analyses revealed statistically significant differences between MCS
responders and partial-responders: significantly greater proportion of MCS re-
sponders had university-level education, were more likely to reside in India or
Russia and be employed, reported‘none’ or ‘light’ bleeding intensity while on treat-
ment, reported greater patient and physician satisfaction with treatment, and had
higher 12-month haemoglobin levels. CONCLUSIONS: Understanding of heteroge-
neity of treatment response is critical for routine clinical practice. Application of
LPA identified two distinct subgroups of women showing differential response to
HRQL from LNG-IUS treatment. All women showed a statistically significant im-
provement in HRQL as measured by the MCS, although this improvement was
greater for a large subset of women in the sample. Country-level differences in
treatment effect on mental HRQL may be subject to cultural or health care practice
differences.
Systemic Disorders/Conditions – Clinical Outcomes Studies
PSY1
TOLERABILITY OF ORAL LONG-ACTING OPIOIDS IN THE TREATMENT OF
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OBJECTIVES: To evaluate the tolerability of oral long-acting opioids (LAOs) in pa-
tients treated for chronic pain. Opioid analgesia is the mainstay of treatment for
moderate to severe chronic pain. While highly effective in relieving pain, it is
limited by adverse events (AEs), especially gastrointestinal and central nervous
system events. AEs may result in additional treatment costs and discontinuation of
therapy, compromising pain management.METHODS:A systematic review of Eng-
lish-language literature published through February 2009 was performed. Random-
ized controlled trials comparing commonly used oral schedule II LAOs with placebo
or another opioid were included. Data on pain measures and pre-specified AEs
(nausea, vomiting, somnolence, constipation, headache, pruritus, and dry mouth)
were collected from each study. For descriptive statistics, treatment-arm data on
tapentadol, oxycodone, oxymorphone, morphine, hydromorphone, and placebo
were pooled across trials. Direct and indirect meta-analyses were performed to
compare AE rates of individual LAOs with placebo and with tapentadol. RESULTS:
Seventy-one published studies met the inclusion criteria. Tapentadol was associ-
ated with the lowest incidence of AEs across the 5 LAOs, with the exception of
headache and dry mouth. The AE incidences for tapentadol, oxycodone, oxymor-
phone, morphine, hydromorphone, and placebo were: nausea: 19.5%, 32.5%, 38.8%,
29.7%, 33.5%, and 8.4%, respectively; vomiting: 7.9%, 16.1%, 19.9%, 15.5%, 15.1%, and
2.4%; somnolence: 10.2%, 24.8%, 18.3%, 33.6%, 50.4%, and 3.7%; constipation: 14.1%,
34.7%, 26.9%, 43.2%, 27.6%, and 6.1%; headache: 13.3%, 11.3%, 9.7%, 3.8%, 5.7%, and
10.4%; pruritus: 5.2%, 16.6%, 15.7%, 20.1%, 20.8%, and 1.5%; and dry mouth: 6.8%,
11.8%, 10.0%, 31.4%, and 2.6% (placebo), with no data for hydromorphone. Indirect
meta-analyses further revealed a significantly favorable tolerability profile of tap-
entadol when compared to oxycodone, oxymorphone, and morphine.
CONCLUSIONS: Opioid-associated AEs are common, but the incidence varied
across the LAOs reviewed. Indirect meta-analyses suggest that tapentadol has a
better tolerability profile than other LAOs.
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OBJECTIVES: Immuno-mediated inflammatory diseases (IMIDs) may coexist
within the same patient. Anti-TNFs have been shown to be effective at treating
IMIDs. The present study aimed at evaluating the prevalence of the coexistence of
selected IMIDs and other comorbidities, characterizing the patient population and
assessing the use of anti-TNFs from a populational standpoint. METHODS: A co-
hort of patients who had received at least one diagnosis of rheumatoid arthritis
(RA), ankylosing spondylitis, psoriatic arthritis, psoriasis (Ps), Crohn’s disease (CD),
ulcerative colitis, or uveitis, between January 2005 and December 2009, was ran-
domly selected from the Régie de l’assurance-maladie du Québec (RAMQ) data-
bases. The coexistence and temporality of the above diagnoses as well as other
predefined chronic conditions were assessed. Characterization and stratification
according to demographics and anti-TNF use (use or no-use) were also performed.
RESULTS: A total of 80,566 patients who had at least one diagnosis of an IMID were
included in this cohort. The study population was on average 53.6 years old (SD:
21.3 years) and was in majority female (60,1%). Most common primary diagnoses
were RA (33.4%), Ps (33.8%) and CD (22.8%) while 3.9% of patients had received at
least one prescription of an anti-TNF medication. In this population, 9.1% of pa-
tients presented with one coexisting IMID diagnosis and 1.4% with 2 or more coex-
isting diagnoses. Among patients who had used an anti-TNF, 27.9% had one coex-
isting IMID diagnosis and 9.1% had 2 or more coexisting diagnoses. Other chronic
comorbidities were found in 82.8% of patients. The most frequent comorbidities
were hypertension (37.2%), cardiovascular diseases (22.4%), diabetes (16.7%) and
osteoporosis (15.7%).CONCLUSIONS:Coexisting IMID diagnoses and comorbidities
are often present in patients with IMID and greatly contribute to the burden of
disease.
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HYPERTENSION, CHRONIC ANXIETY AND DEPRESSION IN ADULT SPANISH
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OBJECTIVES: Obesity is considered a major Public Health issue in most developed
countries nowadays for its wide spread across population groups, as well as its
contribution to the development of chronic diseases. Our objective was to estimate
and better understand the impact of progressively increasing Body Mass Index
(BMI) on diagnosed Diabetes, Heart Attack (HA), Hypertension, Chronic Anxiety
(CA) and Chronic Depression (CD) in adult population. METHODS: Retrospective
analysis of the Spanish 2009 European Health Survey System data base was con-
ducted. Data from population under 18 years old or with BMI under 18.5 or with not
reported BMI were excluded. Sample size of 19,880 adults (89.6% of the initial sam-
ple) was available for analysis. A logistic regression model was constructed for each
of the five dependent variables. Age groups were divided by quartiles. BMI groups
were “18.5–24.9”, “25–29.9”, “30–34.9” (g3) and “35 or more”(g4). RESULTS: Diabetes
prevalence was 7.7%; (OR adjusted for g3:2.3; 95% CI: 2.0–2.7; OR_g4: 4.2; CI:3.4-5.3),
Hypertension prevalence was 23.6%; (OR_g3: 3.4; CI:3.0–3.8; OR_g4: 5.8; CI: 4.8–6.9),
HA prevalence was 2.8%; (OR_g3: 1.7; CI: 1.3–2.1; OR_g4: 1.6; CI: 1.1–2.5), CA preva-
lence was 8.2%; (OR_g3: 1.6; CI: 1.3–1.8; OR_g4: 2.3; CI: 1.8–2.9), CD prevalence was
7.9%; (OR_g3: 1.7; CI: 1.4–2.0; OR_g4: 2.7; CI: 2.2–3.4). All the stated OR reached
statistical significance (p0.05 for OR_g4 in HA and p0.001 for all the rest of them).
CONCLUSIONS: The results show how the risk of the examined comorbidities
largely increases in those patients with BMI35. Considering its potential econom-
ical impact on Public Health, it would be required to design and implement effec-
tive strategies aimed at the early detection of subjects at risk and the provision of
adequate treatment, as well as to establish suitable preventive programmes.
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OBJECTIVES: No direct comparisons have been made between infliximab and
ustekinumab in the treatment of moderate to severe psoriasis. A mixed treatment
comparative (MTC) meta-analysis was conducted to compare the relative efficacy
of infliximab and ustekinumab for the treatment of moderate to severe plague
psoriasis. METHODS: Randomized clinical trials that included infliximab, 5 mg/kg,
ustekinumab 45 mg or ustekinumab 90 mg in the treatment arm and reported PASI
75 and PASI 90 endpoints were identified from a systematic literature search. The
log odds ratio (log OR) was used as the treatment effect measure using both fixed-
effects and random-effects MTC models. Six trials meeting the inclusion criteria
were included in the mixed treatment networks to estimate relative efficacy.
RESULTS: The pooled odds ratio of achieving PASI 75 was 164.4 (95% (CI): 78.3 –
330.1) for infliximab, 77.9 (95% CI: 49.3 - 121.1) for ustekinumab 90 mg and 59.8 (95%
CI: 37.9 - 92.3) for ustekinumab 45 mg compared to placebo. Pairwise comparison
suggested that infliximab is significantly better than and ustekinumab 45 mg to
achieve PASI 75 (p 0.05). Pooled odds ratio of achieving PASI 90 was 172.6 (95% CI:
46.7 - 525.2) for infliximab, 79.6 (95% CI: 39.2 - 155.2) for ustekinumab 90 mg and 65.5
(95% CI: (32.1 - 127.8) for ustekinumab 45 mg. Similarly, there was a statistically
significant difference between infliximab and ustekinumab 45 mg in attaining PASI
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90. Results from random effect models were consistent with fixed effect models.
CONCLUSIONS: Based on this network meta-analysis, a significantly greater pro-
portion of patients with plaque psoriasis are expected to achieve a PASI 75 or PASI
90 response when treated with infliximab 5 mg/kg than with ustekinumab 45 mg or
ustekinumab 90 mg.
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OBJECTIVES: A systematic review of chronic non-malignant pain treatment with
tapentadol and strong opioids.METHODS: Thirteen electronic databases and other
sources were searched until November 2010 for relevant RCTs in chronic moderate/
severe pain investigating at least one WHO step 3 opioid. Two separate analyses
were performed, one for trials reporting the outcome in patients with severe pain,
the other including both moderate and severe pain conditions. Indirect compari-
sons were performed based on a network analysis. Trials with an enriched or an
enriched withdrawal design were excluded. Primary (pain intensity) and a number
of secondary endpoints were evaluated, including pain relief (30% and 50%), patient
global impression of change, quality-of-life, quality-of-sleep, discontinuations,
and selected adverse events. RESULTS: Only 10 trials were eligible for analysis of
patients with severe pain (8 investigating tapentadol and 2 trials comparing bu-
prenorphine patch (TDB) vs placebo). For moderate/severe pain, 42 relevant trials
were identified and indirect comparisons with TDB, transdermal fentanyl (TDF),
hydromorphone, morphine, and oxymorphone were performed. Tapentadol
showed statistically favourable results over oxycodone for pain intensity, 30% and
50% pain relief, patient global impression of change, and quality-of-life. Some of
the most important adverse events of chronic opioid treatment were significantly
less frequent with tapentadol as compared to oxycodone i.e. constipation, nausea,
and vomiting; discontinuations due to these adverse events were found signifi-
cantly reduced with tapentadol. Similar results were obtained for the network
analysis, i.e. tapentadol was superior for the primary outcome (pain intensity) to
hydromorphone and morphine, whereas fentanyl and oxymorphone showed
trends in favour of these treatments. Significantly less frequent gastrointestinal
adverse events were observed using tapentadol in comparison with fentanyl, hy-
dromorphone, morphine, and oxymorphone, apparently leading to significantly
reduced treatment discontinuations (for any reason). CONCLUSIONS: The benefit
risk ratio of tapentadol appears to be better compared to other step 3 opioids.
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PSORIASIS INCIDENCE AND PREVALENCE IN UK PRIMARY CARE
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OBJECTIVES: With previous estimates dating back to 1996-1997, new estimates of
incidence and prevalence are needed to accurately assess the current burden of
psoriasis in the UK. We examined incidence and prevalence in the UK primary care
setting using data from 2008 and 2009. METHODS: THIN, an electronic database
recently validated to study psoriasis in a population-based setting, was used. For
incidence, newly diagnosed patients aged 18 were identified by a psoriasis diag-
nosis (“Read Code”) in medical records between January 1, 2008 and December 31,
2008. For prevalence, a cross-section of patients aged 18 on July 1, 2009 were
selected who had received a psoriasis Read Code in their medical history. Total
person time for 2008 and mid-year patient counts for 2009 were provided as de-
nominators to calculate incidence and prevalence, respectively. Age and sex-spe-
cific rates were calculated and standardized to the UK 2008/2009 population,
respectively. RESULTS: The standardized incidence rate of adult psoriasis in 2008
was 28 (95% CI: 28-29) per 10,000 person-years and highest in 60-69 year olds at 34
(95% CI: 31-36) per 10,000 person-years. Psoriasis prevalence at 01July2009 was
2.83% (95% CI: 2.81-2.86) and highest in 70-79 year olds at 3.49% (95% CI: 3.42-3.56).
Overall, incidence did not vary by sex. However, prevalence in females under 40 was
significantly higher than in males of the same age group: 2.69% (95%CI: 2.65-2.73) vs.
2.42% (95%CI: 2.37-2.44). CONCLUSIONS: Incidence of psoriasis was higher than
rates previously reported in the UK. The high prevalence estimates reported in this
primary care database confirm findings from other European countries and indi-
cate that psoriasis is a condition for which medical attention is commonly sought
and that psoriasis represents a significant burden on the UK healthcare system.
Systemic Disorders/Conditions – Cost Studies
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BUDGET IMPACT ANALYSIS OF BENDAMUSTINE IN THE TREATMENT OF
MULTIPLE MYELOMA IN SPAIN
Mateos MV1, Collar JM2
1Hospital Universitario de Salamanca, Salamanca, Spain, 2Mundipharma Pharmaceuticals,
Madrid, Spain
OBJECTIVES: To estimate the Budget Impact of Bendamustine introduction as a
treatment option for Multiple Myeloma (MM) patients, non-candidates for trans-
plantation, who are likely to be treated with high priced citostatic combinations.
METHODS: A Budget Impact model assuming a prevalent treatable population of
4826 patients with MM, with an incremental rate of 3% per year. The time horizon
considered was three years and the analysis was made from the perspective of the
Spanish Health System. Nine treatment cycles were considered for all the drug
regimens and for the treatment lines included (3 or more). Pharmaceutical expen-
diture on citostatic agents was analyzed, excluding other medical costs. The drug
costs were based on the official ex-factory prices (EFP), discounting the price reduc-
tion recently established by the Spanish Government. The base case scenario was
based on prevalent epidemiological, market research data available and experts
opinion input. The bendamustine scenario considered different drug combinations
and different dosages (90-120mg/m2), depending on the treatment line to analyze.
RESULTS: The drug expenditure for MM treatment is slightly under €120 Mio/year
in Spain. The single cycle costs range from €3 (MelphalanPrednisone) to €5969
(LenalidomideDexamethasone). Bendamustine based treatments would reach
7% to 21% of the treated patients from the first to the last year analyzed. Fifty-four
percent of the Bendamustine treatments considered were combinations with other
expensive drugs (Bortezomib or Thalidomide), where the Bendamustine cost was
only 17% or 21% respectively of the whole treatment regimen. The introduction of
Bendamustine would reduce drug expenditure in €6.6 Mio during the 3 years con-
sidered, expressed in €2011. CONCLUSIONS: The introduction of Bendamustine
would produce drug cost savings in the MM patients, mainly from the 2nd treat-
ment lines onwards. The savings observed in the model were mainly due to the
substitution of high cost combinations like those based on Bortezomib, Thalido-
mide or Lenalidomide therapies.
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OBJECTIVES: Qutenza® is a novel method of action for the treatment of patients
with peripheral neuropathic pain. Therefore it is important to assess the economic
impact of introducing Qutenza® in the Spanish market for the treatment of neuro-
pathic pain in adult patients. METHODS: A budget impact model was developed
using published data on disease prevalence and treatment, population growth,
drug tariffs, health care resource utilization, unit costs and market shares forecasts
for Spain. The perspective of the Spanish national health care system was chosen,
using a 5-year time horizon. Treatments analyzed in this study were carbamaz-
epine, capsaicin cream, pregabalin, lidocaine, duloxetine, amitriptyline, gabapen-
tin and Qutenza®. Costs considered included drug costs, physician visits, diagnos-
tic tests, hospitalisation and complementary non-pharmacological treatment. All
costs referred to EUR 2010. Direct medical annual costs per patient for each treat-
ment were estimated before and after the introduction of Qutenza® in order to
estimate the total annual healthcare costs.RESULTS:Based upon the Spanish adult
population data, the diagnosed population for 2010 suffering from neuropathic
pain was estimated at 235,480 adult patients of whom 217,819 were assumed to
receive treatment for their disease. Increases in the diagnosed and treated popu-
lation were expected with estimates of 236,224 and 218,507 patients in 2015, re-
spectively. Total health care costs over the next 5 years were estimated at €2695
million. Qutenza® was estimated to grow from 1.6% in the first year up to 5.6% in
the fifth year. Under these conditions, total healthcare costs were estimated at
€2,679 million. Mean annual costs per patient before the introduction of Qutenza®
were estimated at €2,059 and at €2,046 after its introduction. CONCLUSIONS: The
introduction of Qutenza® is likely to decrease the budget impact of neuropathic
pain treatments for the Spanish national health care system. Overall savings in the
economic burden of €16.7 million were found over the next 5 years.
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OBJECTIVES: Wegener’s granulomatosis (WG) is a rare disease, fatal without ther-
apy. Cyclophosphamide (CYC) administered by oral or intravenous route is the gold
standard. Intravenous CYC (IVCYC) is the reference in France. However, rituximab,
mainly used for treating B-cell lymphomas, is being tested in clinical trials for
treating WG. To estimate the economic impact of using rituximab to induce remis-
sion in WG patients. METHODS: The six months induction treatment cost was
evaluated for treating a hypothetical cohort of prevalent cases constituted by
newly diagnosed and relapsing cases. In France, WG prevalence was estimated at
about 3 per 100 000 inhabitants. Treatment cost included costs of hospital stays,
drugs, follow-up and therapeutic acts. The costs over five years were estimated by
a model which take into account efficacy data of each treatment (rates of remis-
sion, failure and infectious complications) and the proportion of patients treated
each year. Scenarios (S) were tested on hypothetical rituximab indications: pre-
scribed to 10% of newly diagnosed patients and 50% of relapsing patients in S1 and
100% of relapsing patients in S2. RESULTS: The number of prevalent cases was
estimated to be about 1,884 in France in 2010. Treatment of these cases with the
reference strategy using IVCYC costed 166 millions € over 5 years. The introduction
of rituximab in WG therapies induced an overcost of 900 K€ in S1 and 2 millions € in
S2 over 5 years. CONCLUSIONS: In our analysis which is not exhaustive, others
treatments used to induce remission were not evaluated. Results revealed that
rituximab should possibly be indicated when cyclophosphamide is contra-indi-
cated and when patients are refractory to previous treatments. Efficacy data of
rituximab use in long term (remission, relapses and complications induced) are
expected. Results of rituximab efficacy evaluated as a maintenance therapy are
also expected.
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